Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

$Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )$

Matched targeted therapy for paediatric patients with relapsed, refractory or...

Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA

$Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )$

Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for...

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor...

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

$Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )$

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )

AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...

Prof Marion Subklewe - University of Munich, Munich, Germany

$AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )$

KRd versus VRd in patients with newly diagnosed multiple myeloma

Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )

Researchers identify mutation that causes resistance to venetoclax in CLL...

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Researchers identify mutation that causes resistance to venetoclax in CLL patients ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )

Daratumumab increases PFS in patients with transplant-ineligible multiple...

Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for...

Dr Tait Shanafelt - Standford University, Stanford, USA

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )

Resistance mechanisms to venetoclax in patients with progressive CLL

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Dr Alok Khorana - Cleveland Clinic, Cleveland, USA

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )

More from ecancer